SG11202104807YA - Lipid nanoparticle formulations - Google Patents

Lipid nanoparticle formulations

Info

Publication number
SG11202104807YA
SG11202104807YA SG11202104807YA SG11202104807YA SG11202104807YA SG 11202104807Y A SG11202104807Y A SG 11202104807YA SG 11202104807Y A SG11202104807Y A SG 11202104807YA SG 11202104807Y A SG11202104807Y A SG 11202104807YA SG 11202104807Y A SG11202104807Y A SG 11202104807YA
Authority
SG
Singapore
Prior art keywords
lipid nanoparticle
nanoparticle formulations
formulations
lipid
nanoparticle
Prior art date
Application number
SG11202104807YA
Other languages
English (en)
Inventor
James Heyes
Adam Judge
Kieu Mong Lam
Lorne Ralph Palmer
Petra Schreiner
Original Assignee
Arbutus Biopharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arbutus Biopharma Corp filed Critical Arbutus Biopharma Corp
Publication of SG11202104807YA publication Critical patent/SG11202104807YA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/505—Erythropoietin [EPO]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
SG11202104807YA 2018-11-09 2019-11-08 Lipid nanoparticle formulations SG11202104807YA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862758088P 2018-11-09 2018-11-09
PCT/US2019/060582 WO2020097540A1 (fr) 2018-11-09 2019-11-08 Formulations de nanoparticules lipidiques

Publications (1)

Publication Number Publication Date
SG11202104807YA true SG11202104807YA (en) 2021-06-29

Family

ID=70611206

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202104807YA SG11202104807YA (en) 2018-11-09 2019-11-08 Lipid nanoparticle formulations

Country Status (13)

Country Link
US (1) US20220000778A1 (fr)
EP (1) EP3877521A4 (fr)
JP (1) JP2022506956A (fr)
KR (1) KR20210105889A (fr)
CN (1) CN113286882A (fr)
AU (1) AU2019376161A1 (fr)
BR (1) BR112021008982A2 (fr)
CA (1) CA3119071A1 (fr)
EA (1) EA202191313A1 (fr)
IL (1) IL282995A (fr)
MX (1) MX2021005389A (fr)
SG (1) SG11202104807YA (fr)
WO (1) WO2020097540A1 (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7506670B2 (ja) * 2018-11-09 2024-06-26 アルブータス・バイオファーマー・コーポレイション 脂質ナノ粒子製剤
AU2020352552A1 (en) 2019-09-23 2022-03-17 Omega Therapeutics, Inc. Compositions and methods for modulating hepatocyte nuclear factor 4-alpha (HNF4α) gene expression
AU2020355000A1 (en) 2019-09-23 2022-03-17 Omega Therapeutics, Inc. Compositions and methods for modulating apolipoprotein B (APOB) gene expression
GB2621760B (en) * 2020-03-04 2024-09-11 Verve Therapeutics Inc A method for reducing the risk of coronary disease
JP2023517326A (ja) 2020-03-11 2023-04-25 オメガ セラピューティクス， インコーポレイテッド フォークヘッドボックスｐ３（ｆｏｘｐ３）遺伝子発現をモジュレートするための組成物および方法
FI20215508A1 (en) 2020-04-09 2021-10-10 Niemelae Erik Johan Mimetic nanoparticles to prevent the spread of new coronaviruses and reduce the rate of infection
US11771652B2 (en) 2020-11-06 2023-10-03 Sanofi Lipid nanoparticles for delivering mRNA vaccines
CN113509542A (zh) * 2021-04-20 2021-10-19 嘉晨西海(杭州)生物技术有限公司 一种基于mRNA的表达白介素12针对肿瘤的药物及其制备方法
WO2023283359A2 (fr) 2021-07-07 2023-01-12 Omega Therapeutics, Inc. Compositions et procédés de modulation de l'expression génique de la protéine 1 du récepteur frizzled secrété (sfrp1)
JP2024528697A (ja) 2021-07-20 2024-07-30 エイジーエス・セラピューティクス・ソシエテ・パール・アクシオン・サンプリフィエ 微細藻類由来の細胞外小胞、その調製および使用
CA3132191A1 (fr) * 2021-09-28 2023-03-28 Providence Therapeutics Holdings Inc. Compositions et methodes de prevention et/ou de traitement de la covid-19
KR20230053998A (ko) 2021-10-15 2023-04-24 (주)지노믹트리 mRNA 발현을 위한 유전자 구조체
AU2022382104A1 (en) * 2021-11-05 2024-06-20 Sanofi Respiratory syncytial virus rna vaccine
WO2023144127A1 (fr) 2022-01-31 2023-08-03 Ags Therapeutics Sas Vésicules extracellulaires provenant de microalgues, leur biodistribution suite à leur administration, et leurs utilisations
CN118804743A (zh) * 2022-03-04 2024-10-18 益杰立科(上海)生物科技有限公司 靶向递送系统和方法
KR20230145791A (ko) 2022-04-11 2023-10-18 연세대학교 원주산학협력단 mRNA 백신을 위한 양이온성 지질 나노입자
WO2023232976A1 (fr) 2022-06-03 2023-12-07 Ags Therapeutics Sas Vésicules extracellulaires provenant de microalgues génétiquement modifiées contenant une cargaison chargée de manière endogène, leur préparation et utilisations
TW202404936A (zh) * 2022-06-08 2024-02-01 中央研究院 脂質與包含脂質之奈米顆粒及其用途
WO2024088808A1 (fr) 2022-10-24 2024-05-02 Ags Therapeutics Sas Vésicules extracellulaires provenant de microalgues, leur biodistribution lors d'une administration intranasale, et leurs utilisations

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103260611A (zh) * 2010-09-30 2013-08-21 默沙东公司 用于寡核苷酸递送的低分子量阳离子脂质
JP2013545727A (ja) * 2010-10-21 2013-12-26 メルク・シャープ・アンド・ドーム・コーポレーション オリゴヌクレオチド送達用の新規低分子量カチオン性脂質
JP6275655B2 (ja) * 2012-02-24 2018-02-07 プロティバ バイオセラピューティクス インコーポレイテッド トリアルキルカチオン性脂質およびその使用方法
AU2013249548A1 (en) * 2012-04-19 2014-11-06 Sirna Therapeutics, Inc. Novel diester and triester based low molecular weight, biodegradable cationic lipids for oligonucleotide delivery
CN110974981A (zh) * 2013-07-23 2020-04-10 野草莓树生物制药公司 用于递送信使rna的组合物和方法
EP3201338B1 (fr) * 2014-10-02 2021-11-03 Arbutus Biopharma Corporation Compositions et méthodes d'extinction de l'expression du gène du virus de l'hépatite b

Also Published As

Publication number Publication date
EP3877521A1 (fr) 2021-09-15
CA3119071A1 (fr) 2020-05-14
CN113286882A (zh) 2021-08-20
IL282995A (en) 2021-06-30
WO2020097540A1 (fr) 2020-05-14
AU2019376161A1 (en) 2021-06-03
EA202191313A1 (ru) 2022-01-26
BR112021008982A2 (pt) 2021-08-10
MX2021005389A (es) 2021-07-21
US20220000778A1 (en) 2022-01-06
KR20210105889A (ko) 2021-08-27
JP2022506956A (ja) 2022-01-17
EP3877521A4 (fr) 2022-07-27

Similar Documents

Publication Publication Date Title
IL282995A (en) Formulations of lipid nanoparticles
IL273541A (en) formulations
IL268697A (en) Formulations
GB2559774B (en) Oral cannabinoid formulations
EP3877522A4 (fr) Formulations de nanoparticules lipidiques
GB201611547D0 (en) Oral cannabinoid formulations
EP3247363A4 (fr) Compositions de nanoparticules lipidiques
EP3247398A4 (fr) Compositions de nanoparticules lipidiques
IL269630A (en) Niraprib formulations
EP3662913A4 (fr) Nanoparticules lipidiques contenant un acide nucléique
IL269621A (en) Niraparib formulations
IL273282A (en) Niraprib formulations
EP3452079C0 (fr) Formulations d'insuline comprenant du polysorbate 80
ZA201607310B (en) Lubricant formulations
PL3582627T3 (pl) Formulacje stabilne podczas przechowywania
ZA201903101B (en) Pharmaceutical formulations
IL281425A (en) Nanoparticle formulations
IL271673A (en) Preparations containing drugs with increased solubility
SG10201913501RA (en) Liposomal formulations
IL271908A (en) Over-compressed pharmaceutical preparations
SG11202011823SA (en) Activator-nucleator formulations
IL268195A (en) Solid fosmetpantothenate formulations
GB201819028D0 (en) Butanol-based formulations
GB201808386D0 (en) Formulations
GB201804545D0 (en) Formulations